Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study

Noemi Puig, Vania T.M. Hungria, Ajai Chari, Faith E. Davies, Gordon Cook, Roman Hájek, Kathryn E. Morgan, Jim Omel, Evangelos Terpos, Michael A. Thompson, Saad Usmani, Jorge Vela-Ojeda, Katja Weisel, Mira Armour, Kaili Ren, Dasha Cherepanov, Dawn Marie Stull, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 4269–4272.

https://doi.org/10.1182/blood-2022-163074

Published: 2022

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study

Blood (2018) 132 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2018-99-112846

Published: 2018

Journal Articles

Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

Blood (2017) 130 (Supplement 1): 5419.

https://doi.org/10.1182/blood.V130.Suppl_1.5419.5419

Published: 2017

Journal Articles

Treatment Patterns and Survival Outcomes in Latin American Patients with Newly Diagnosed Multiple Myeloma: A Retrospective Medical Chart Review Study, 2008-2016

Vania T M Hungria, MD PhD, Deborah M. Martinez-Banos, Christian Ramos Penafiel, Carlos Eduardo Miguel, Jorge Vela-Ojeda, MD PhD, Guillermina Remaggi, Fernando Barroso Duarte, Carmen Cao, Maria Silvana Cugliari, Telma Santos, Eduardo Santos, Gerardo Machnicki, Jennifer Hsiang-Ling Lin, Yen-Wen Chen, Paula Barreyro

Blood (2017) 130 (Supplement 1): 2113.

https://doi.org/10.1182/blood.V130.Suppl_1.2113.2113

Published: 2017

Journal Articles

Cytogenetics As a Prognostic Factor Of The Overall Survival (OS) Of Mexican Patients With Myelodysplastic Syndrome (MDS)

Maria Guadalupe Rodriguez-Gonzalez, MD, Yaneth Martinez-Ibarra, MD, Jorge Vela-Ojeda, MD, PhD, Kevin Nacho-Vargas, MD, Luis Meillon, MD, Yamile Fattel, MD, Julio Robledo, MD, MSc, Tonatiuh Romero-Salas, PhD, Moises Xolotl-Castillo, MD

Blood (2013) 122 (21): 5236.

https://doi.org/10.1182/blood.V122.21.5236.5236

Published: 2013

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.

Anuj Mahindra, MD, David Vesole, MD, PhD, Matt E. Kalaycio, MD, Jorge Vela-Ojeda, MD, Smriti Shrestha, MS, MA, Mei-Jie Zhang, PhD, Angela Dispenzieri, MD, Gustavo A. Milone, MD, Sagar Lonial, MD, Parameswaran N. Hari, MD, MS

Blood (2009) 114 (22): 532.

https://doi.org/10.1182/blood.V114.22.532.532

Published: 2009

Journal Articles

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Blood (2008) 112 (11): 4275.

https://doi.org/10.1182/blood.V112.11.4275.4275

Published: 2008

Journal Articles

Correlation between FOXP3 Gene Polymorphisms in Donors, and the Severity of Acute Graft-Versus-Host Disease in Patients after Related Allogeneic Stem Cell Transplantation.

Yocanxochitl Perfecto-Avalos, MSc, Jose R. Borbolla Escoboza, MD, Luis M. Villela-Martiez, MD, Sean P. Scott, PhD, Jorge Vela-Ojeda, MD, PhD, Oscar Gonzalez-Ramella, MD, PhD, Severiano Baltazar-Arellano, MD, Manuel A. Lopez-Hernandez, MD

Blood (2007) 110 (11): 3233.

https://doi.org/10.1182/blood.V110.11.3233.3233

Published: 2007

Journal Articles

Rituximab in Warfarin Resistance Treatment in Patients with Thrombophilia Due to Primary Antiphospholipid Syndrome: A Pilot Study.

Jaime Garcia Chavez, Moises L. Mendoza-Torres, Jorge Vela-Ojeda, Eduardo E. Reynoso

Blood (2007) 110 (11): 4001.

https://doi.org/10.1182/blood.V110.11.4001.4001

Published: 2007

Journal Articles

Efficacy and Safety of Rituximab+CHOP in IR and Maintenance Therapy with Rituximab vs Observation in De Novo Aggressive Non-Hodgkin Lymphoma.

Francisco Tripp, MD, Enrique Báez, MD, Elsa Ávila, MD, Severiano Baltazar, MD, Oscar Garcés, MD, Gustavo Reyes, MD, Benjamín Batista, MD, Alva Zaragoza, MD, Jorge Vela-Ojeda, MD, Luis Villela, MD

Blood (2007) 110 (11): 4489.

https://doi.org/10.1182/blood.V110.11.4489.4489

Published: 2007

Journal Articles

Parvovirus B19 and Aplastic Anemia: Case Control Study: Preliminary Report from the ITESM Hematology Study Group.

Jose R. Borbolla Escoboza, MD, Marcos E. Garza-Madrid, MD, Luis Villela, MD, Manuel A. Lopez-Hernandez, MD, Jorge Vela-Ojeda, MD

Blood (2005) 106 (11): 3765.

https://doi.org/10.1182/blood.V106.11.3765.3765

Published: 2005

Journal Articles

Treatment of Refractory Chronic Immune Thrombocytopaenic Purpura (ITP) with Rituximab: Report of a Cases Series.

Jaime Garcia-Chavez, MD, Jorge Vela-Ojeda, MD, Jose C. Gonzalez-Acosta, MD, Roberto Ovilla-Martinez, MD

Blood (2005) 106 (11): 4007.

https://doi.org/10.1182/blood.V106.11.4007.4007

Published: 2005

Journal Articles

The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study.

Guillermo J. Ruiz-Arguelles, MD, FACP, FRCP(Glasg), David Gomez-Almaguer, MD, Amelia Morales-Toquero, MD, Cesar H. Gutierrez-Aguirre, Jorge Vela-Ojeda, Miriam A. Garcia-Ruiz-Esparza, MD, Carlos Manzano, MD, Amado Karduss, MD, Abraham Sumoza, MD, Carmino de-Souza, MD, Eliana Miranda, MD, Sergio Giralt, MD

Blood (2005) 106 (11): 4838.

https://doi.org/10.1182/blood.V106.11.4838.4838

Published: 2005

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning in Patients with Myeloid Leukemias: Results of a Prospective Study of the Latin American Cooperative Onco Hematology Group (LACOHG).

Guillermo J. Ruiz-Arguelles, David Gómez-Almaguer, José D. Gómez-Rangel, Jorge Vela-Ojeda, Amado Kardus, Olga G. Cantú-Rodríguez, José C. Jaime-Pérez, Oscar González-Llano, José L. Herrera-Garza

Blood (2004) 104 (11): 5154.

https://doi.org/10.1182/blood.V104.11.5154.5154

Published: 2004

NARROW

Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study

Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

Treatment Patterns and Survival Outcomes in Latin American Patients with Newly Diagnosed Multiple Myeloma: A Retrospective Medical Chart Review Study, 2008-2016

Cytogenetics As a Prognostic Factor Of The Overall Survival (OS) Of Mexican Patients With Myelodysplastic Syndrome (MDS)

Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Correlation between FOXP3 Gene Polymorphisms in Donors, and the Severity of Acute Graft-Versus-Host Disease in Patients after Related Allogeneic Stem Cell Transplantation.

Rituximab in Warfarin Resistance Treatment in Patients with Thrombophilia Due to Primary Antiphospholipid Syndrome: A Pilot Study.

Efficacy and Safety of Rituximab+CHOP in IR and Maintenance Therapy with Rituximab vs Observation in De Novo Aggressive Non-Hodgkin Lymphoma.

Parvovirus B19 and Aplastic Anemia: Case Control Study: Preliminary Report from the ITESM Hematology Study Group.

Treatment of Refractory Chronic Immune Thrombocytopaenic Purpura (ITP) with Rituximab: Report of a Cases Series.

The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study.

Allogeneic Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning in Patients with Myeloid Leukemias: Results of a Prospective Study of the Latin American Cooperative Onco Hematology Group (LACOHG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only